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Background: The study objective was to investigate the prognostic utility and patient specific characteristics of ST2, assessed with a novel 
sensitive assay.
Methods: In an international multicenter cohort design, we prospectively enrolled 1,091 patients presenting with acute dyspnea to the emergency 
department (ED). ST2 was measured in a blinded fashion using a novel assay and compared to BNP and NT-proBNP. The primary endpoint was 
mortality at 1-year and the prognostic value of ST2 was evaluated in comparison and in addition to BNP and NT-proBNP.
Results: Median ST2 concentrations were higher among decedents than survivors (85.3 U/ml vs. 43.0 U/ml, p<0.001). ST2 levels were significantly 
elevated in patients with impaired left ventricular ejection fraction (p<0.001).In ROC analysis, the AUC for ST2 (0.72) as a predictor of 1 year 
mortality was comparable to BNP (0.71) and NT-proBNP (0.73). The combinations of ST2 and BNP or NT-proBNP (using median values) improved 
prediction of 1-year mortality by Kaplan Meier analysis (p<0.001). In multivariable analysis, ST2 values above the median (50 U/ml) significantly 
predicted 1 year mortality in all dyspneic patients (HR 2.31, p<0.001) as well as in the subgroups of acute decompensated heart failure patients 
(HR 1.68, p=0.05) and patients with non-cardiac causes of dyspnea (HR 3.72, p=0.002).
Conclusions: In dyspneic patients, ST2 is a strong and independent predictor of 1 year mortality and may improve risk stratification already 
provided by BNP or NT-proBNP.
